55.27 F
New York, US
April 19, 2025
PreetNama
English News

California health official calls for pausing Moderna Covid-19 vaccine after allergic reactions reported at one clinic

California’s State Epidemiologist, Dr Erica Pan, called for pausing administration of Moderna’s coronavirus vaccine due to a high-than-usual number of severe allergic reactions.

A higher-than-usual number of possible allergic reactions were reported with a specific lot of Moderna vaccine administered at one community vaccination clinic. Fewer than 10 individuals required medical attention over the span of 24 hours,” Pan said in a California Department of Public Health statement.

More than 330,000 doses of this particular lot were distributed to 287 health care providers across California earlier this month, the statement said.

Moderna, the Centres for Disease Control and Prevention, and the US Food and Drug Administration are currently undertaking a review of the batch in question.

The epidemiologist acknowledged that getting any vaccine is not without risk, but available data on similar vaccines show that one severe allergic reaction per 100,000 inoculations can be expected, well below the current posting.

Related posts

Rocket falls near Iraqi base hosting US contractors

On Punjab

Good Newwz song Sauda Khara Khara teaser: Akshay Kumar one-ups his Bala number with Nagin dance. Watch

On Punjab

he plans for AstraZeneca’s new headquarters and large R&D campus in Cambridge were unveiled in 2013, but its costs and timeframe have exceeded the initial estimate of 330 million pounds and an aimed completion date of 2016. AstraZeneca, which has a large portfolio of treatments for diseases such as cancer, heart disease and diabetes, said the centre would support research into specialised medicines and next-generation therapeutics, including gene-editing and cell therapies. “We will have advances that could come to the clinic in the next three, four years, that can lead to really effective new drugs in various aspects of treating cancer,” Dr Susan Galbraith, AstraZeneca’s executive vice president, Oncology Research & Development, told Reuters in an interview. “I’m very optimistic about the fact that we can make a big difference to this disease in the coming decade”.

On Punjab